Driehaus Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Driehaus Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.4M	Buy	+564,039	New	+$9.09M	0.08%	260
2024 Q3	–	Sell	-535,717	Closed	-$6.31M	–	420
2024 Q2	$6.31M	Sell	535,717 -5,821	-1%	-$67.9K	0.06%	250
2024 Q1	$6.42M	Sell	541,538 -487,030	-47%	-$6.49M	0.06%	267
2023 Q4	$12.6M	Sell	1,028,568 -6,055	-0.6%	-$55.1K	0.15%	210
2023 Q3	$9.96M	Sell	1,034,623 -1,312	-0.1%	-$13.4K	0.13%	208
2023 Q2	$9.32M	Buy	1,035,935 +20,816	+2%	+$192K	0.12%	220
2023 Q1	$7.98M	Buy	1,015,119 +3,748	+0.4%	+$28K	0.11%	246
2022 Q4	$6.84M	Buy	1,011,371 +481,932	+91%	+$2.58M	0.1%	245
2022 Q3	$7.68M	Buy	+529,439	New	+$7.4M	0.12%	227
2021 Q1	–	Sell	-50,000	Closed	-$950K	–	475
2020 Q4	$950K	Buy	+50,000	New	+$857K	0.02%	327

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Driehaus Capital Management's KALV Position: Q1 2026 in Review

Driehaus Capital Management opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 564,039 shares worth $11.4M. The stake represents 0.08% of the portfolio and ranks #260 among its holdings. This is a return to the name: Driehaus Capital Management previously reported a position in KALV as recently as Q2 2024.

Driehaus Capital Management first reported a position in KALV in Q4 2020 and has held it in 10 quarters since. The position peaked at $12.6M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Driehaus Capital Management held 564,039 shares of KalVista Pharmaceuticals worth $11.4M as of Q1 2026.
KalVista Pharmaceuticals was a new Driehaus Capital Management position in Q1 2026.
KalVista Pharmaceuticals made up 0.08% of Driehaus Capital Management's portfolio in Q1 2026, its #260 holding.
Driehaus Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2020 and has held it in 10 quarters since.
Driehaus Capital Management's KalVista Pharmaceuticals position peaked at $12.6M in Q4 2023.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.